Karl Claxton
#88,583
Most Influential Person Now
Researcher
Karl Claxton's AcademicInfluence.com Rankings
Download Badge
Economics
Karl Claxton's Degrees
- PhD Health Economics University of York
- Masters Health Economics University of York
- Bachelors Economics University of York
Similar Degrees You Can Earn
Why Is Karl Claxton Influential?
(Suggest an Edit or Addition)According to Wikipedia, Professor Karl Claxton is a health economist at the University of York. He has a PhD in Economics, an MSc in Health Economics and a BA in Economics from the University of York. He was a Harkness Fellow at the Harvard T.H. Chan School of Public Health and from 1999 until 2007 he held an adjunct appointment there as Assistant Professor of Health and Decision Sciences. He has been a member of the National Institute for Health and Care Excellence Appraisal Committee since 1999. He is the co-editor of the Journal of Health Economics.
Karl Claxton's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Decision Modelling for Health Economic Evaluation (2006) (1384)
- Representing uncertainty: the role of cost-effectiveness acceptability curves. (2001) (1030)
- The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. (1999) (875)
- Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. (2016) (736)
- Review of guidelines for good practice in decision-analytic modelling in health technology assessment. (2004) (676)
- Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. (2015) (651)
- Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016) (581)
- A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002) (472)
- Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. (2005) (459)
- The NICE Cost-Effectiveness Threshold (2012) (441)
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment (2012) (421)
- An economic approach to clinical trial design and research priority-setting. (1996) (409)
- The NICE cost-effectiveness threshold: what it is and what that means. (2008) (405)
- Expected Value of Sample Information Calculations in Medical Decision Modeling (2004) (366)
- Whither trial-based economic evaluation for health care decision making? (2006) (362)
- A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. (2004) (347)
- Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. (2009) (291)
- Using Value of Information Analysis to Prioritise Health Research (2012) (234)
- Value based pricing for NHS drugs: an opportunity not to be missed? (2008) (218)
- Orphan drugs and the NHS: should we value rarity? (2005) (212)
- Discounting and decision making in the economic evaluation of health-care technologies. (2011) (198)
- Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. (2001) (196)
- Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence (2007) (192)
- Should patients have a greater role in valuing health states? (2005) (182)
- Exploring Uncertainty in Cost-Effectiveness Analysis (2012) (177)
- Discounting in Economic Evaluations (2018) (176)
- The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. (2016) (169)
- Characterizing structural uncertainty in decision analytic models: a review and application of methods. (2009) (167)
- Assessing Quality in Decision Analytic Cost-Effectiveness Models (2000) (162)
- The Value of Implementation and the Value of Information: Combined and Uneven Development (2008) (156)
- Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. (1999) (153)
- Appropriate perspectives for health care decisions. (2010) (150)
- Wound healing and TIME; new concepts and scientific applications. (2005) (146)
- A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. (2006) (142)
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. (2003) (139)
- Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data (2018) (136)
- Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? (2005) (129)
- Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. (2012) (125)
- OFT, VBP: QED? (2007) (112)
- Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. (2006) (109)
- When is evidence sufficient? (2005) (105)
- Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? (2015) (103)
- Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. (2006) (100)
- Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. (2006) (98)
- Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. (2012) (98)
- Dangerous omissions: the consequences of ignoring decision uncertainty. (2011) (92)
- Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. (2007) (86)
- Value for money and the Quality and Outcomes Framework in primary care in the UK NHS. (2010) (82)
- The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions? (2008) (82)
- A Framework for Addressing Structural Uncertainty in Decision Models (2011) (80)
- The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis (2014) (79)
- A dynamic programming approach to the efficient design of clinical trials. (2001) (78)
- Probabilistic analysis and computationally expensive models: Necessary and required? (2006) (73)
- Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data (2015) (73)
- The heterogeneity of schizophrenia in disease states (2004) (70)
- Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. (2009) (68)
- Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis (2002) (68)
- Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses (2007) (67)
- Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. (2017) (64)
- Eliciting distributions to populate decision analytic models. (2010) (63)
- Selecting treatments: a decision theoretic approach (2000) (62)
- The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. (2007) (62)
- Methods to elicit experts’ beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration (2011) (62)
- Addressing Adoption and Research Design Decisions Simultaneously (2011) (56)
- Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. (2018) (55)
- Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs (2010) (55)
- Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions (2007) (54)
- Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. (2009) (54)
- Orphan drugs revisited. (2006) (54)
- An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery (2006) (53)
- Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. (2017) (53)
- Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: Are current international norms fit for purpose? (2014) (52)
- Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS (2011) (52)
- Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling (2000) (50)
- Efficiency, Equity, and Budgetary Policies (2007) (50)
- Incorporation of uncertainty in health economic modelling studies (2012) (49)
- Policy: Development goals should enable decision-making (2015) (45)
- Budget allocation and the revealed social rate of time preference for health. (2012) (44)
- Continuing the multiple sclerosis risk sharing scheme is unjustified (2010) (43)
- Using value of information analysis to inform publicly funded research priorities (2005) (42)
- Supporting the development of a health benefits package in Malawi (2018) (40)
- Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. (2019) (40)
- A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence (2005) (39)
- Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods. (2010) (39)
- Decision analysis for resource allocation in health care (2008) (38)
- Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design (2009) (38)
- Decision Analytic Modelling in the Economic Evaluation of Health Technologies (2012) (38)
- Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration (2008) (37)
- Uncertainty and value of information when allocating resources within and between healthcare programmes (2008) (36)
- Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse (2013) (36)
- A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. (2016) (34)
- Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. (2010) (32)
- Cancer Drugs Fund requires further reform (2016) (30)
- Defining and characterising structural uncertainty in decision analytic models (2006) (30)
- Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses (2018) (29)
- Redefining the analytical approach to pharmacoeconomics. (1999) (29)
- Assessing the economic challenges posed by orphan drugs: A comment on Drummond et al. (2007) (28)
- What next after GDP-based cost-effectiveness thresholds? (2020) (28)
- When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. (2013) (27)
- The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all‐cause and disease specific models of mortality (2018) (26)
- How to estimate the health benefits of additional research and changing clinical practice (2015) (25)
- Development goals should enable decision-making. (2015) (25)
- A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE (2005) (23)
- When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development? (2013) (23)
- It ’ s Just Evaluation for Decision Making : Recent Developments in , and Challenges for , Cost-Effectiveness Research (2003) (22)
- BAYESIAN VALUE-OF-INFORMATION ANALYSIS (2001) (22)
- The Humble Economist: Tony Culyer on Health, Health Care and Social Decision Making (2012) (21)
- Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity (2020) (20)
- Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome (2006) (20)
- Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis (2012) (20)
- Accounting for Timing when Assessing Health-Related Policies (2019) (20)
- A Dynamic Programming Approach to Efficient Clinical Trial Design (2001) (19)
- Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement (2020) (18)
- Rights, responsibilities and NICE: a rejoinder to Harris (2007) (18)
- Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. (2021) (17)
- Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. (2015) (17)
- Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts (2020) (17)
- Introduction. Bayesian approaches to technology assessment and decision making. (2001) (17)
- Supporting the development of an essential health package: principles and initial assessment for Malawi (2016) (16)
- Why licensing authorities need to consider the net value of new drugs in assigning review priorities: Addressing the tension between licensing and reimbursement (2008) (16)
- Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies (2011) (16)
- Real Economics Needs to Reflect Real Decisions (2012) (15)
- Expected health benefits of additional evidence: Principles, methods and applications (2013) (15)
- Reviewing the evidence for wound bed preparation. (2006) (14)
- Decision-making with Uncertainty: The Value of Information (2006) (14)
- Valuing health outcomes: developing better defaults based on health opportunity costs (2020) (13)
- What is, and What “What is” Means (1998) (13)
- International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. (2016) (13)
- Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure (2020) (13)
- Modelling the behaviour of general practitioners: a theoretical foundation for studies of fundholding (1994) (12)
- How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13 (2021) (11)
- Assessing health opportunity costs for the Indian health care systems (2019) (10)
- Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data (2016) (10)
- The Value of Innovation (2009) (10)
- Bayesian approaches to technology assessment and decision making (2001) (9)
- Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries (2020) (9)
- When Is Evidence Sufficient? A framework for making use of all available information in medical decision making and for deciding whether more is needed. (2005) (8)
- Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE (2016) (8)
- Developing a reference protocol for expert elicitation in healthcare decision making (2019) (8)
- Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom (2010) (8)
- Searching for a threshold – Not so… (2007) (7)
- Informing Decisions in Global Health: Cost Per DALY Thresholds and Health Opportunity Costs (2017) (7)
- The VALUE OF INNOVATION REPORT BY THE DECISION SUPPORT UNIT Contributors (Alphabetically) (2009) (7)
- Testing the evidence (2005) (6)
- Reference Case Methods for Expert Elicitation in Health Care Decision Making (2021) (6)
- Analyzing Uncertainty in Cost-effectiveness For Decision-making (2011) (6)
- Understanding Harris’ understanding of CEA: Is cost effective resource allocation undone? (2013) (6)
- Is an ounce of prevention worth a pound of cure? : Estimates of the impact of English public health grant on mortality and morbidity (2019) (6)
- Incorporating health inequality concerns into cost- effectiveness analysis - Overview (2012) (5)
- Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries (2021) (5)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting (2020) (5)
- Appraising the value of evidence generation activities: an HIV modelling study (2018) (5)
- Mathematical programming for the optimal allocation of health care resources (2005) (5)
- A stitch in time: preserving peace on Bougainville (2013) (5)
- Systematic review of the literature on the cost-effectiveness threshold (2015) (5)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting. (2020) (5)
- HG4 The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis: Theoretical Framework and Application (2011) (4)
- Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury. (2016) (4)
- How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework (2018) (4)
- rarity ? Orphan drugs and the NHS : should we value (2005) (4)
- Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014 (2021) (4)
- Analysing and presenting simulation output from probabilistic models (2006) (4)
- Cost consequences: implicit, opaque and anti scientific (2017) (4)
- Practical metrics for establishing the health benefits of research to support research prioritisation (2020) (3)
- Shared interests, enduring cooperation: the future of Australia–PNG police engagement (2014) (3)
- The Value of Further Research: The Added Value of Individual-Participant Level Data (2019) (3)
- How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15 (2022) (3)
- Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.” by Sampson, Firth, and Towse (2021) (3)
- Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system (2018) (3)
- Decision Models Need to be “Fit for Purpose” for Decision‐Making: Response to Caro et al. (2007) (3)
- Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems (2021) (2)
- Negative pressure wound therapy for severe pressure ulcers: Evidence synthesis and the value of further research (2011) (2)
- A Cost‐Effectiveness Analysis of Intradiscal Electrothermal Therapy Compared with Circumferential Lumbar Fusion (2018) (2)
- Bayesian econometric modelling of observational data for cost‐effectiveness analysis: establishing the value of negative pressure wound therapy in the healing of open surgical wounds (2020) (2)
- Surgical wounds healing by secondary intention: characterising and quantifying the problem, identifying effective treatments, and assessing the feasibility of conducting a randomised controlled trial of negative pressure wound therapy versus usual care (2019) (2)
- Information Analysis, Value of (2014) (2)
- Drugs for exceptionally rare diseases: a commentary on Hughes et al (2006) (2)
- Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Portfolio Design (2007) (2)
- PHP52 BUDGETARY POLICIES AND AVAILABLE ACTIONS: A GENERALISATION OF DECISION RULES FOR ALLOCATION AND RESEARCH DECISIONS (2009) (1)
- Comment: Positive tails and normative dogs. (2018) (1)
- Enhanced external counterpulsation for stable angina or heart failure: a systematic review and economic evaluation (2009) (1)
- PRM168 An Integrated Formal Framework for Reimbursement, Research and Pricing Deliberations in Health Technology Assessment (2012) (1)
- The value of clinical information : an economic approach to research priority setting (1996) (1)
- PHP204 Appropriate Methods for Economic Evaluation of Programmes with Costs and Effects Extending Across Sectors (2012) (1)
- The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programme including the SWHSI feasibility RCT (2020) (1)
- CO1 Individual Decisions and Social Value: A Conceptual Framework to Explore Alternative Decision Making Approaches and the Value of Heterogeneity in the Era of Individualized Care (2012) (1)
- Unrelated future costs and unrelated future benefits: Reflections on NICE Guidance to the Methods of Technology Appraisal Keywords: health technology assessment, economic analysis, cost effectiveness analysis, costing, unrelated future costs (2016) (1)
- Routine pre-operative testing regression analysis report (2012) (1)
- Modelling the Cost Effectiveness of Multiple Sclerosis Therapies Studies Group (2003) (1)
- The International Decision Support Initiative (iDSI) Reference Case for Health Economic Evaluation (2019) (1)
- Papua New Guinea at 40: Signs of a New Political Culture? (2015) (1)
- Supporting the Development of Health Benefits Packages (HBPs): Principles and Initial Assessment for Malawi (2020) (1)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting. (2020) (1)
- Bougainville 1988-1998 : five serches for security in the North Solomons Province of Papua New Guinea (1998) (1)
- Cancer Drugs Fund requires further reform : Reliance on “real world” observational data undermines evidence base for clinical practice (2016) (1)
- Resolving the ‘cost-effective but unaffordable’ ‘paradox’: estimating the health opportunity costs of non-marginal budget impacts : Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts (2018) (1)
- Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care (2018) (1)
- Does public long-term care expenditure improve care-related quality of life in England? (2020) (1)
- Does public long-term care expenditure improve care-related quality of life of service users in England? (2021) (1)
- Excluded studies: cost-effectiveness review (2012) (0)
- Turnbull and Buck: summary of relevant pre-operative test results and relevant complications (2012) (0)
- FIGURE 17, [Sensitivity of the outcome elasticity...]. (2015) (0)
- THC volume 26 issue 4 Cover and Back matter (2010) (0)
- MS3 A DEMONSTRATION OF THE USE OF BAYESIAN DECISION THEORY TO OPTIMISE DRUG DEVELOPMENT PROGRAMMES (2003) (0)
- DimensionsofDesignSpace: aDecision-TheoreticApproachto OptimalResearchPortfolioDesign (2004) (0)
- The link between NHS spending and mortality: estimating the cost of a life-year in England (2015) (0)
- More long‐term care for better health care and vice versa: investigating the mortality effects of interactions between these public sectors (2023) (0)
- Methodological issues concerning evidence on effectiveness (2006) (0)
- Apparent patient flow in the study by Gnocchi et al. (2012) (0)
- Systematic review of clinical effectiveness: quality assessment of randomised controlled trial (2012) (0)
- Systematic review of clinical effectiveness: tabulation of excluded studies (2012) (0)
- The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17. (2023) (0)
- An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial (2021) (0)
- Search strategies for cost-effectiveness review (2012) (0)
- The Value of Innovation [Internet] (2009) (0)
- Systematic review of clinical effectiveness: quality assessment of non-randomised studies (2012) (0)
- Review of the adverse effects of venepuncture: quantity of research available (2012) (0)
- TABLE 53, [Table showing respiratory problems spend models with various indicators of MFF and need]. (2015) (0)
- Review of the adverse effects of pulmonary function testing: quantity of research available (2012) (0)
- PHP14 HAVE YOUR CAKE OR EAT IT: DO DECISIONS BASED ON COSTEFFECTIVENESS UNDERMINE INCENTIVES FOR RESEARCH AND DEVELOPMENT? (2009) (0)
- General Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations. (2022) (0)
- Using Meta-Analysis to Plan Further Research (2020) (0)
- PRM171 Optimal Shopping: An Evauation of Decision Rules in Cost-Effectiveness Analysis (CEA) (2012) (0)
- Comparing the Value of Different HTA Decision Making Process: Evaluating the Evaluators (2013) (0)
- Screening for Early onset Group B Streptococcus in the UK: cost-effectiveness and expected value of information analysis (2007) (0)
- Access, The Cancer Drugs Fund (2018) (0)
- ID1: DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT (2001) (0)
- The Value of Sample Information: A Decision Theoretic Approach to Research Design (2007) (0)
- Accelerating access to new drugs in NHS harmful (2016) (0)
- In recognition of Anthony J. Culyer (2007) (0)
- INTRODUCTION (2001) (0)
- Survey of current practice on pre-operative testing in ASA grade 1 and ASA grade 2 (2012) (0)
- PSY33 A COST-UTILITY ANALYSIS OF IDET COMPARED WITH SPINAL FUSION (2009) (0)
- IN2 VALUE OF INFORMATION ANALYSIS OF THE DECISION BETWEEN CIPROFLOXACIN VS. TRIMETHOPRIM SULPHAMETHOXAZOLE FOR EMPIRICAL TREATMENT OF WOMEN WITH PYELONEPHRITIS (2002) (0)
- Pharmacoeconomics 2008; 26 (9): 733-744 (2008) (0)
- TABLE 87, [Table showing cost of life...]. (2015) (0)
- TABLE 89, [Table showing expenditure and outcome...]. (2015) (0)
- Data extraction tables for cost-effectiveness review (2012) (0)
- The link between NHS spending, mortality and the cost of a life-year (2015) (0)
- Economic impact of decision-making and the introduction of new drugs in practice (1997) (0)
- Policy context and conceptual framework (2015) (0)
- Applying a Bayesian Approach to the Iterative Process to Health Technology Assessment (2007) (0)
- Bayesian Econometric Modelling Of Observational Data For Cost-Effectiveness Analysis. (2015) (0)
- Implications for a policy threshold (2015) (0)
- Review of the adverse effects of venepuncture and pulmonary function testing: methods (2012) (0)
- PCV48 USING EXPERT ELICITATION TO INFORM ADOPTION AND RESEARCH DECISIONS FOR ENHANCED EXTERNAL COUNTERPULSATION IN ANGINA (2009) (0)
- Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi (2021) (0)
- Cost-effectiveness of pre-operative testing of full blood count, electrolytes and renal function and pulmonary function in the management of ASA grade 1 and grade 2 surgical patients undergoing minor and intermediate surgery (2012) (0)
- PHP117 The Cost-Effectiveness Threshold: The Results of A Novel Literature Review Method (2011) (0)
- The Irrelevance of the Error Probability? Summary Measures of Decision Uncertainty (2007) (0)
- Acknowledgement to Referees (2016) (0)
- Translating mortality effects into life-years and quality-adjusted life-years (2015) (0)
- Systematic review of clinical effectiveness: MEDLINE search strategies (2012) (0)
This paper list is powered by the following services:
Other Resources About Karl Claxton
What Schools Are Affiliated With Karl Claxton?
Karl Claxton is affiliated with the following schools:
